VIDEO: Modifying venetoclax dosing may help manage cytopenia in AML
Most patients with acute myeloid leukemia who responded to treatment with venetoclax plus azacitidine in the VIALE-A study required dosing modifications to manage cytopenia, according to a presentation from ASH Annual Meeting and Exposition.
Delays between cycles or within-cycle reductions of venetoclax dosing days were common, according to Keith W. Pratz, MD, director of the Leukemia Program at Penn Medicine.
“Eighty-five percent of patients after achieving remission in the venetoclax arm had a subsequent grade 4 neutropenia or thrombocytopenia at some point after achieving remission. The median time to that next period of severe cytopenias was 40 days or more in the venetoclax arm and a delay in the next cycle occurred in 78% of patients in the venetoclax arm,” Pratz told Healio in a video interview.
Collapse
Pratz KW, et al. Abstract 1944. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.